Welcome to our dedicated page for Silence Therapeutics Plc American Depository Share news (Ticker: SLN), a resource for investors and traders seeking the latest updates and insights on Silence Therapeutics Plc American Depository Share stock.
Silence Therapeutics Plc (symbol: SLN) is a pioneering biotechnology company dedicated to developing innovative therapies by leveraging the body's natural RNA interference (RNAi) mechanism. This cutting-edge technology allows the selective inhibition of any gene in the genome, effectively silencing the production of disease-causing proteins.
Silence Therapeutics utilizes proprietary delivery systems to target therapeutic RNA molecules directly to specific cells, enhancing the specificity and efficacy of the treatment. The company's proprietary RNA chemistries and delivery systems are designed to improve the stability of these molecules and ensure efficient delivery, making their technology well-suited for treating life-threatening diseases.
The company's product pipeline includes two promising therapies:
- SLN360: This therapy is designed to temporarily block the message of a specific gene associated with increased cardiovascular risk. By silencing the LPA gene, SLN360 lowers the levels of lipoprotein(a) [Lp(a)], potentially reducing the risk of heart diseases, heart attacks, and strokes.
- SLN124: Aimed at addressing anemia, SLN124 targets the TMPRSS6 gene to prevent the liver from producing a hormone that controls iron levels in the body, hepcidin. By increasing hepcidin levels, SLN124 reduces iron levels in the blood, thereby promoting the production of healthy red blood cells.
Silence Therapeutics is at the forefront of RNAi-based therapies, with ongoing projects and collaborations to advance their groundbreaking treatments. For the latest updates on the company's achievements and developments, visit www.silence-therapeutics.com.
Rhea-AI Summary
Silence Therapeutics plc, Nasdaq: SLN, will participate in a fireside chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on February 7th. The live webcast can be accessed via the Investors section of the Silence website. An archived replay of the webcast will be available following the conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.44%
Tags
-
Rhea-AI Summary
Silence Therapeutics plc (Nasdaq: SLN) promotes Curtis Rambaran, MD to Chief Medical Officer and Marie Wikström Lindholm, PhD to Chief Scientific Officer. Both have been instrumental to the company's clinical and scientific successes. Curtis' experience in leading successful early and late-stage development programs combined with his background in cardiovascular medicine will be invaluable to Silence's next phase of growth. Marie's extensive work in oligonucleotide therapeutics is impressive, and the company looks forward to her leading their efforts to innovate and further expand their footprint as a global siRNA leader.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.28%
Tags
-
Rhea-AI Summary
Silence Therapeutics plc (Nasdaq: SLN) reported strong execution across its mRNAi GOLD™ platform, including positive data from the multiple dose study for zerlasiran in patients with high Lp(a) and stable ASCVD, and progress in the SLN124 phase 1/2 study in polycythemia vera. The company also reviewed recent business highlights and financial results for the third quarter ended September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.33%
Tags
Rhea-AI Summary
Silence Therapeutics plc (Nasdaq: SLN) announced that Craig Tooman, President and CEO, will present a corporate update at the Jefferies London Healthcare Conference on November 15th. The webcast can be accessed via the Investors section of the Silence website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.49%
Tags
-
Rhea-AI Summary
Silence Therapeutics announces positive results from the multiple dose component of the APOLLO phase 1 study of zerlasiran. Zerlasiran demonstrated significant reductions in lipoprotein(a) levels of up to 99% and remained around 90% lower than baseline at the end of the treatment period. The drug also showed a dose-dependent reduction in LDL cholesterol and apolipoprotein B. Zerlasiran was well tolerated with no safety concerns identified.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.25%
Tags
-
Rhea-AI Summary
Silence Therapeutics plc to participate in fireside chat at Chardan's Genetic Medicines Conference on October 3rd.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.61%
Tags
Rhea-AI Summary
Silence Therapeutics announces participation in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.7%
Tags
-
Rhea-AI Summary
Silence Therapeutics plc, Nasdaq: SLN, reported its financial results for Q2 2023, with a net loss after tax of £10.4 million. The company achieved several milestones, including completing dosing in the APOLLO phase 1 study and achieving enrollment in the ALPACAR-360 phase 2 study. Silence also received milestone payments of $10.0 million from AstraZeneca and $4.0 million from Hansoh. Revenue for Q2 2023 was £9.1 million, compared to £3.6 million in Q2 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.21%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.34%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.61%
Tags
FAQ
What is the current stock price of Silence Therapeutics Plc American Depository Share (SLN)?
The current stock price of Silence Therapeutics Plc American Depository Share (SLN) is $5.61 as of February 4, 2025.
What is the market cap of Silence Therapeutics Plc American Depository Share (SLN)?
The market cap of Silence Therapeutics Plc American Depository Share (SLN) is approximately 246.9M.
What is Silence Therapeutics Plc?
Silence Therapeutics Plc is a biotechnology company focused on developing medicines using RNA interference technology to silence disease-causing genes.
What is RNA interference (RNAi)?
RNA interference (RNAi) is a natural biological process where RNA molecules inhibit gene expression, effectively silencing specific genes.
What is SLN360 therapy?
SLN360 is a therapy designed to lower the levels of lipoprotein(a) [Lp(a)] by silencing the LPA gene, potentially reducing cardiovascular risks.
What is SLN124 therapy?
SLN124 aims to reduce anemia by silencing the TMPRSS6 gene, increasing hepcidin levels to lower blood iron and promote healthy red blood cell production.
How does Silence Therapeutics target specific cells?
The company uses proprietary delivery systems to direct therapeutic RNA molecules specifically to target cells, enhancing treatment specificity and efficacy.
What diseases are Silence Therapeutics' therapies targeting?
Silence Therapeutics' therapies target cardiovascular diseases, anemia, and potentially other life-threatening conditions through gene silencing.
How does SLN360 reduce cardiovascular risks?
SLN360 silences the LPA gene, lowering levels of Lp(a), which is associated with reduced risks of heart diseases, heart attacks, and strokes.
What is the role of hepcidin in SLN124 therapy?
Hepcidin is a hormone that controls iron levels in the body. SLN124 increases hepcidin levels to reduce blood iron and promote red blood cell production.
Where can I find more information about Silence Therapeutics' projects?
For more details on the company's projects and developments, visit their official website at www.silence-therapeutics.com.
What makes Silence Therapeutics unique?
Silence Therapeutics stands out for its proprietary RNAi technology and delivery systems, allowing precise and effective gene silencing to treat serious diseases.
Silence Therapeutics Plc American Depository Share